SHANDONG BOAN BIOTECHNOLOGY CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.8 HKD | 0.00% |
|
+0.93% | -36.77% |
| 05-28 | China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug | MT |
| 05-27 | Shandong Boan Biotechnology GCTB Drug NMPA's Marketing Approval | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 8,906 | 7,175 | 4,630 | - | - |
| Enterprise Value (EV) 1 | 8,974 | 7,379 | 5,124 | 5,268 | 5,311 |
| P/E ratio | -26.1 x | -61.3 x | -25.1 x | -32.4 x | -116 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 17.3 x | 11.6 x | 6.41 x | 4.98 x | 3.31 x |
| EV / Revenue | 17.4 x | 11.9 x | 7.09 x | 5.66 x | 3.8 x |
| EV / EBITDA | -36.6 x | -156 x | -70 x | -823 x | 47.9 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | 6.28 x | 5.44 x | 4.08 x | 4.67 x | 4.86 x |
| Nbr of stocks (in thousands) | 509,278 | 509,278 | 509,278 | - | - |
| Reference price 2 | 17.49 | 14.09 | 9.091 | 9.091 | 9.091 |
| Announcement Date | 27/03/23 | 25/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 516 | 618.1 | 722.5 | 930.4 | 1,399 |
| EBITDA 1 | -245.5 | -47.17 | -73.16 | -6.403 | 110.9 |
| EBIT 1 | -318.3 | -129.9 | -177.7 | -119.4 | -1.444 |
| Operating Margin | -61.7% | -21.02% | -24.59% | -12.84% | -0.1% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.6700 | -0.2300 | -0.3628 | -0.2809 | -0.0785 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 27/03/23 | 25/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | 68.2 | 204 | 494 | 639 | 681 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.2779 x | -4.326 x | -6.751 x | -99.72 x | 6.144 x |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -22.3% | -8.72% | -15.1% | -13.5% | -4.12% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share 2 | 2.790 | 2.590 | 2.230 | 1.950 | 1.870 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 122 | 104 | 215 | 110 | 110 |
| Capex / Sales | 23.61% | 16.87% | 29.78% | 11.82% | 7.86% |
| Announcement Date | 27/03/23 | 25/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
9.091
CNY
Average target price
10.44
CNY
Spread / Average Target
+14.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.77% | 639M | |
| -2.50% | 90.28B | |
| -1.97% | 39.5B | |
| -15.47% | 31.71B | |
| +61.28% | 26.41B | |
| -22.81% | 14.34B | |
| -8.82% | 12.89B | |
| -11.77% | 11.8B | |
| -45.97% | 10.95B | |
| +3.30% | 8.85B |
- Stock Market
- Equities
- 6955 Stock
- Financials Shandong Boan Biotechnology Co., Ltd.
